AI + palbociclib (HR+/HER2- metastatic 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LETROZOLE` `DRUG-PALBOCICLIB`

ID	`REG-AI-PALBOCICLIB`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-BREAST-METASTATIC-2024` `SRC-NCCN-BREAST-2025`

Notes

PALOMA-2: PFS benefit (~10-month improvement vs letrozole alone) in HR+/HER2- metastatic 1L. Premenopausal patients require ovarian suppression (LHRH agonist) added. For postmenopausal with bone-only disease + endocrine-sensitive: this is workhorse 1L.

Used By

Handbook Chapters

HB-BREAST-HR-POS-HER2-NEG-1L - HR+/HER2- metastatic breast cancer: first-line reasoning

Handbook Questions

HQ-BREAST-HR-POS-1L-001 - HQ-BREAST-HR-POS-1L-001

Indication

IND-BREAST-HR-POS-MAINT-CDK46I - IND-BREAST-HR-POS-MAINT-CDK46I